A major limiting factor in discovering new insights into the pathogenesis of sarcoidosis is the lack of a viable disease model. FSR has identified research within a Sarcoidosis Disease Model as one of the critical investments of our focus, and has designated significant funding toward this initiative. In a two-phase plan, FSR is funding early stage research in this area. The FSR Model Grant opportunity will serve to ignite additional research and will help bridge funding for much-needed larger investments into the disease model space from industry, academia, and venture philanthropy. This initial grant’s Request For Applications (RFA) was opened in Fall 2016 with funding selections made in Spring 2017. A grant amount, totaling $750,000, was awarded to five projects towards the development, characterization, or improvement of a sarcoidosis disease model. In early 2019, an RFA for a continuation of funding was opened as a closed competitive process, applicable only to previously FSR-funded disease model investigators. A grant amount, totaling $300,000 for three awardees, will allow the those partners to complete 18-month projects. Following robust early-stage research made possible by this grant, FSR continues to strategize to fund another $1.5 million-plus for a the next phase of the grant with the goal of the resulting research to stimulate interest from long-term investors.

 

Continuation of Funding Awardees (2019)
  • Ohio State University – Elliott Crouser, MD, Landon Locke, PhD, Mark Julian, MS
    Ex Vivo Human Granuloma Model of Sarcoidosis: Phase 2 
  • Yale School of Medicine – Erica Herzog, MD, PhD
    Development of an ex vivo mimetic of the Sarcoidosis lung microenvironment 
  • Medical University of Vienna – Thomas Weichhart, PhD
    Further Characterization and Improvement of a Novel Mouse Model that Spontaneously Develops Progressive Sarcoidosis by Chronic Activation of mTORC1 

 

Disease Model Grant Awardees (2017)
  • Medical University of Vienna – Thomas Weichhart, PhD
    Characterization and Improvement of a Novel Mouse Model that Spontaneously Develops Progressive Sarcoidosis by Chronic Activation of mTORC1
  • Ohio State University – Elliott Crouser, MD, Larry Schlesinger, MD, Wolfgang Sadee, Dr.rer.nat, Peter White, PhD
    A Novel In Vitro Human Granuloma Model of Sarcoidosis
  • University of Freiburg – Peggy Engelhard, PhD, Gernot Zissel,PhD, Joachim Müller-Quernheim, MD, Marina A. Freudenberg, MD
    Models for the investigations of the involvement of type I interferon (IFN-aB) in the pathogenesis of sarcoidosis
  • University of Hull, York Medical School – Simon Hart, MBChB, PhD
    Development and application of a multi-scale computational model of sarcoidosis to predict therapeutic approaches for non-self-resolving disease
  • Yale School of Medicine – Erica Herzog, MD, PhD
    Development of an ex vivo mimetic of the Sarcoidosis lung microenvironment
Publications:

The five awardees from the initial grant funding were asked to present their project plans at the 2017 European Respiratory Society’s annual conference. Read ERS Journal’s editorial about the project, New Advances in Development of Sarc Models (Disease Model Symposium)

View the original request for applications announcement.